Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 93 |
| Active Pipeline (Recruiting Now) | 37 (17) |
| Completed vs Stopped Early | 37 / 14 (15.1%) |
| Median Closed Actual Enrollment | 203 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Peking University People's Hospital | Beijing, Beijing Municipality | 7 |
| Sun Yat-sen University Cancer Center | Guangzhou, Guangdong | 6 |
| Beijing Cancer Hospital | Beijing, Beijing Municipality | 6 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT06081920 | A Study of IBI363 in Subjects With Advanced Melanoma | Phase II | RECRUITING |
| NCT06238843 | A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (C | Phase III | ACTIVE NOT RECRUITING |
| NCT06797297 | A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced o | Phase II | ACTIVE NOT RECRUITING |
| NCT05607680 | A Study of IBI362 in Participants With Obesity or Overweight | Phase III | COMPLETED |
Explore interactive annual charts and M&A subsidiary rollups in the Innovent Biologics (Suzhou) Co Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.